Publications by authors named "Reda Khan"
Article Synopsis
- Eculizumab is a primary treatment for paroxysmal nocturnal hemoglobinuria (PNH), but some patients may become resistant to it, leading to a condition known as eculizumab refractory PNH.
- The study systematically reviewed 70 relevant studies on treatments for eculizumab refractory PNH, ultimately identifying four multicenter clinical trials that focused on drugs like pegcetacoplan, danicopan, and iptacopan.
- The findings suggest that treatment plans should be tailored to individual patient needs, and further randomized controlled trials are necessary to improve treatment guidelines for eculizumab refractory PNH.
